Clinical and demographic characteristics of the training and testing cohorts stratified by cluster
| . | Training cohort . | Testing cohort . | ||||
|---|---|---|---|---|---|---|
| . | Cluster 1 (n = 80) . | Cluster 2 (n = 92) . | P value . | Cluster 1 (n = 35) . | Cluster 2 (n = 37) . | P value . |
| Age (y) | 34.8 ± 11.8 | 36.3 ± 12.0 | .41 | 38.5 ± 9.1 | 38.2 ± 11.8 | .91 |
| Female/male (n) | 43/37 | 51/41 | .09 | 17/22 | 28/22 | .29 |
| HgSS | 71 | 76 | .35 | 29 | 31 | .76 |
| HgSC | 5 | 12 | .20 | 4 | 7 | .749 |
| HgSB | 4 | 4 | 1.00 | 2 | 3 | 1.00 |
| BMI (kg/m2) | 25.1 ± 6.0 | 24.8 ± 5.3 | .74 | 22.8 ± 3.8 | 24.2 ± 6.6 | .28 |
| HU therapy | 40 (50%) | 48 (52%) | .88 | 16 (53%) | 27 (69%) | .21 |
| ACS | 73 (91%) | 71 (77%) | .013 | 23 (62%) | 20 (45%) | .18 |
| WBC (10−3/mm3) | 10.7 ± 3.6 | 9.0 ± 3.4 | .002 | 10.2 ± 3.5 | 8.6 ± 3.3 | .039 |
| Hg (g/dL) | 8.5 ± 1.6 | 9.1 ± 1.8 | .045 | 8.7 ± 2.0 | 8.8 ± 1.7 | .77 |
| Creatinine (mg/dL) | 0.98 ± 0.83 | 1.22 ± 1.58 | .22 | 1.02 ± 1.38 | 1.27 ± 1.80 | .47 |
| HbF (g/dL) | 7.1 ± 5.3 | 8.0 ± 7.6 | .39 | 8.5 ± 8.7 | 9.4 ± 7.8 | .73 |
| LDH (U/L) | 453 ± 222 | 394 ± 195 | .07 | 378 ± 170 | 350 ± 154 | .50 |
| Bilirubin (mg/dL) | 3.9 ± 3.1 | 2.3 ± 1.5 | .0001 | 2.8 ± 1.6 | 2.2 ± 1.6 | .13 |
| AST (U/L) | 57.0 ± 69.3 | 41.5 ± 21.2 | .060 | 47.1 ± 27.4 | 37.4 ± 17.0 | .07 |
| Peak TRV (≥2.5 m/s) | 39.1% | 26.3% | .109 | 60.0% | 50.0% | .487 |
| Peak TRV (≥3.0 m/s) | 12.5% | 5.0% | .134 | 14.3% | 7.5% | .461 |
| . | Training cohort . | Testing cohort . | ||||
|---|---|---|---|---|---|---|
| . | Cluster 1 (n = 80) . | Cluster 2 (n = 92) . | P value . | Cluster 1 (n = 35) . | Cluster 2 (n = 37) . | P value . |
| Age (y) | 34.8 ± 11.8 | 36.3 ± 12.0 | .41 | 38.5 ± 9.1 | 38.2 ± 11.8 | .91 |
| Female/male (n) | 43/37 | 51/41 | .09 | 17/22 | 28/22 | .29 |
| HgSS | 71 | 76 | .35 | 29 | 31 | .76 |
| HgSC | 5 | 12 | .20 | 4 | 7 | .749 |
| HgSB | 4 | 4 | 1.00 | 2 | 3 | 1.00 |
| BMI (kg/m2) | 25.1 ± 6.0 | 24.8 ± 5.3 | .74 | 22.8 ± 3.8 | 24.2 ± 6.6 | .28 |
| HU therapy | 40 (50%) | 48 (52%) | .88 | 16 (53%) | 27 (69%) | .21 |
| ACS | 73 (91%) | 71 (77%) | .013 | 23 (62%) | 20 (45%) | .18 |
| WBC (10−3/mm3) | 10.7 ± 3.6 | 9.0 ± 3.4 | .002 | 10.2 ± 3.5 | 8.6 ± 3.3 | .039 |
| Hg (g/dL) | 8.5 ± 1.6 | 9.1 ± 1.8 | .045 | 8.7 ± 2.0 | 8.8 ± 1.7 | .77 |
| Creatinine (mg/dL) | 0.98 ± 0.83 | 1.22 ± 1.58 | .22 | 1.02 ± 1.38 | 1.27 ± 1.80 | .47 |
| HbF (g/dL) | 7.1 ± 5.3 | 8.0 ± 7.6 | .39 | 8.5 ± 8.7 | 9.4 ± 7.8 | .73 |
| LDH (U/L) | 453 ± 222 | 394 ± 195 | .07 | 378 ± 170 | 350 ± 154 | .50 |
| Bilirubin (mg/dL) | 3.9 ± 3.1 | 2.3 ± 1.5 | .0001 | 2.8 ± 1.6 | 2.2 ± 1.6 | .13 |
| AST (U/L) | 57.0 ± 69.3 | 41.5 ± 21.2 | .060 | 47.1 ± 27.4 | 37.4 ± 17.0 | .07 |
| Peak TRV (≥2.5 m/s) | 39.1% | 26.3% | .109 | 60.0% | 50.0% | .487 |
| Peak TRV (≥3.0 m/s) | 12.5% | 5.0% | .134 | 14.3% | 7.5% | .461 |
BMI, body mass index; HbF, hemoglobin F; HU, hydroxyurea; LDH, lactate dehydrogenase.